(STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated ...

The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology, AmorphOX®. UPPSALA, Sweden, April 10, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ...